- Home
- MLNK vs ARDX Comparison
MLNK vs ARDX Comparison
Compare MLNK & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLNK
- ARDX
- Stock Information
- Founded
- MLNK 1998
- ARDX 2007
- Country
- MLNK United States
- ARDX United States
- Employees
- MLNK N/A
- ARDX N/A
- Industry
- MLNK Computer Software: Prepackaged Software
- ARDX Biotechnology: Pharmaceutical Preparations
- Sector
- MLNK Technology
- ARDX Health Care
- Exchange
- MLNK Nasdaq
- ARDX Nasdaq
- Market Cap
- MLNK 1.5B
- ARDX 1.4B
- IPO Year
- MLNK 2021
- ARDX 2014
- Fundamental
- Price
- MLNK $18.41
- ARDX $5.06
- Analyst Decision
- MLNK Hold
- ARDX Buy
- Analyst Count
- MLNK 6
- ARDX 8
- Target Price
- MLNK $22.58
- ARDX $9.93
- AVG Volume (30 Days)
- MLNK 196.5K
- ARDX 3.6M
- Earning Date
- MLNK 03-06-2025
- ARDX 02-20-2025
- Dividend Yield
- MLNK N/A
- ARDX N/A
- EPS Growth
- MLNK N/A
- ARDX N/A
- EPS
- MLNK N/A
- ARDX N/A
- Revenue
- MLNK $311,440,000.00
- ARDX $333,615,000.00
- Revenue This Year
- MLNK $5.87
- ARDX $169.30
- Revenue Next Year
- MLNK $6.37
- ARDX $14.87
- P/E Ratio
- MLNK N/A
- ARDX N/A
- Revenue Growth
- MLNK 3.96
- ARDX 168.06
- 52 Week Low
- MLNK $16.49
- ARDX $4.32
- 52 Week High
- MLNK $25.33
- ARDX $9.83
- Technical
- Relative Strength Index (RSI)
- MLNK 31.78
- ARDX 41.70
- Support Level
- MLNK $18.49
- ARDX $5.37
- Resistance Level
- MLNK $19.40
- ARDX $6.55
- Average True Range (ATR)
- MLNK 0.39
- ARDX 0.31
- MACD
- MLNK -0.04
- ARDX -0.02
- Stochastic Oscillator
- MLNK 7.02
- ARDX 0.67
About MLNK MeridianLink Inc.
MeridianLink Inc is a cloud-based software solution for financial institutions, including banks, credit unions, mortgage lenders, specialty lending providers, and consumer reporting agencies. It generates maximum revenue from Lending Software Solutions.
About ARDX Ardelyx Inc.
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.